

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Aminophylline Tablets (100mg) from National Medical Products Administration of China (the “NMPA”), being under type 3 chemical drug, regarded as passing the consistency evaluation and the third of such approvals for the PRC entities. Aminophylline Tablet is mainly used in the relief of wheezing symptoms in bronchial asthma, wheezing bronchitis and obstructive emphysema, and can also be used in treatment of asthma caused by cardiogenic pulmonary edema. The Group’s Aminophylline bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

The Board is also pleased to announce that the Group has obtained the approvals for drug production and registration for Procaterol Hydrochloride Inhalation Solution (0.5ml : 50µg) and Ademetionine 1,4-Butanedisulfonate for Injection (0.5g) from the NMPA, being under type 3 and type 4 chemical drug respectively and regarded as passing the consistency evaluation. Procaterol Hydrochloride Inhalation Solution is mainly used in the relief of various symptoms based on airflow limitation in bronchial asthma, chronic bronchitis and emphysema. Ademetionine 1,4-Butanedisulfonate for Injection is mainly used in treatment of pre-cirrhotic and cirrhotic intrahepatic cholestasis, as well as intrahepatic cholestasis of pregnancy.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 24 November 2025

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.